Sotera Health Company (SHC) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents a mixed picture. Financial performance is stable with slight growth, but there is a cautious tone in guidance and potential regulatory impacts. The Q&A reveals some concerns about growth slowdowns and regulatory changes, but also highlights operational resilience and customer satisfaction. The market cap suggests moderate sensitivity to these factors, leading to a neutral prediction for stock movement.
Key Financial Performance
Revenue Revenues increased by 10% to $280 million or 6.5% on a constant currency basis compared to the first quarter 2025. This growth was driven by favorable pricing, foreign currency benefits, and improved volume mix.
Net Income Net income on a GAAP basis for the quarter was $27 million or $0.09 per diluted share. Adjusted EPS increased to $0.18 per share, an improvement of approximately 29% from the prior year, driven by operational improvements and favorable financial conditions.
Adjusted EBITDA Adjusted EBITDA grew 10.5% to $135 million or 6.9% on a constant currency basis, while adjusted EBITDA margins expanded over 20 basis points. This was driven by favorable pricing, foreign currency benefits, and improved volume mix.
Interest Expense Interest expense for Q1 2026 improved by $6 million to $35 million compared to the prior year quarter. This improvement was driven by the term loan repricing, debt paydown, and lower interest rates.
Sterigenics Revenue Sterigenics delivered 9.7% revenue growth to $186 million or 6.1% on a constant currency basis. Growth was driven by favorable pricing of 4.5%, a foreign currency benefit of 3.6%, and improved volume mix of 1.6%, partially offset by localized weather impacts in the U.S.
Nordion Revenue Nordion's first quarter revenue increased 29% to $42 million or 25.8% on a constant currency basis. This was driven by increased volume mix of 23.7% due to the timing of Cobalt-60 harvest schedules, foreign currency tailwinds of 3.2%, and a pricing benefit of 2.1%.
Nordion Segment Income Nordion segment income increased approximately 36% to $24 million or 33.1% on a constant currency basis, with segment income margins expanding more than 290 basis points to 56.4%. This was driven by higher volume and mix, foreign currency benefits, and favorable pricing, partially offset by inflation.
Nelson Labs Revenue Nelson Labs revenue declined 0.7% to $52 million or 3.8% on a constant currency basis. Pricing benefits of 2.8% and a foreign currency benefit of 3.1% were more than offset by the change in volume and mix.
Nelson Labs Segment Income Segment income decreased by 11.5% to $15 million or 15.1% on a constant currency basis, with margins of 28%. This decline was due to lower volume and mix, partially offset by favorable pricing and a foreign currency tailwind.
Operating Cash Flow Generated $29 million in positive operating cash flow, inclusive of a $34 million payment for a previously disclosed legal settlement.
Capital Expenditures Capital expenditures for the quarter totaled $46 million, driven by investments in Sterigenics greenfield expansions, EO facility upgrades, and Cobalt-60 development projects.
Liquidity Position The company's liquidity position remains strong with over $900 million of available liquidity as of the end of Q1 2026.
Net Leverage Ratio Finished the quarter with a net leverage ratio of 3.2x, nearing the long-term target range of 2 to 3x.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Revenue Growth: The company reported a 6.5% constant currency revenue growth and a 6.9% constant currency adjusted EBITDA growth in Q1 2026. Sterigenics achieved 6.1% constant currency revenue growth, while Nordion grew by 25.8%.
Profitability: Adjusted EBITDA margins expanded by over 20 basis points. Nordion's segment income margins expanded by more than 290 basis points to 56.4%.
Cost Management: Interest expense improved by $6 million due to term loan repricing and debt paydown, along with lower interest rates.
Cash Flow and Liquidity: Generated $29 million in positive operating cash flow despite a $34 million legal settlement payment. The company has over $900 million in available liquidity.
Leadership Transition: Michael Petras announced a leadership transition, with Alton Shader appointed as the new CEO effective May 26, 2026. Petras will transition to the role of Executive Chair.
Governance Changes: Ken Krause joined the Board of Directors, bringing extensive experience in strategy, finance, and governance. Two private equity Board members, Dean Mihas and Robert Knauss, completed their service.
Legal Developments: All 8 bellwether personal injury cases in Georgia were dismissed due to lack of reliable scientific support for the claims. The court's decision is expected to influence the evaluation of remaining cases.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Legal Risks: The company faces ongoing legal challenges related to personal injury cases in Georgia. Although recent court decisions have dismissed bellwether cases, these cases are subject to appeal, and the broader legal risks remain a concern for the company.
Operational Risks: Localized weather impacts in the U.S. during Q1 caused a 1.7% headwind to Sterigenics volumes, highlighting potential vulnerabilities to weather-related disruptions.
Segment-Specific Challenges: Nelson Labs experienced a 0.7% revenue decline and an 11.5% decrease in segment income due to lower volume and mix, which could impact overall profitability if not addressed.
Cost and Inflation Pressures: Higher costs and inflation partially offset revenue growth in segments like Nordion, indicating ongoing challenges in managing operational expenses.
Interest Rate and Debt Management: While interest expenses have improved, the company still faces significant interest costs, with projections between $135 million and $145 million for 2026, which could impact financial flexibility.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2026 Revenue Growth: Total company revenue is expected to grow to a range of $1.233 billion to $1.251 billion, representing 5% to 6.5% constant currency growth, with an estimated 100 basis point foreign currency benefit.
Adjusted EBITDA: Expected to improve to a range of $632 million to $641 million, representing 5.5% to 7% constant currency growth, with an estimated 100 basis point impact from foreign currency.
Segment Revenue Growth: Sterigenics is expected to deliver mid- to high single-digit constant currency revenue growth year-over-year. Nordion is expected to grow constant currency revenue in the low to mid-single digits, with first-half revenue representing approximately 40% to 45% of full-year revenue. Nelson Labs is expected to achieve low single-digit constant currency revenue growth, with a slight return to growth in Q2.
Pricing and Margins: Total company pricing is expected to be approximately the midpoint of the 3% to 4% long-term range. Nelson Labs' segment income margins are expected to improve throughout the year, resulting in full-year margins in the low to mid-30s.
Interest Expense: Projected to be between $135 million and $145 million for 2026.
Tax Rate: Effective tax rate applicable to adjusted net income is expected to be in the range of 27% to 29%.
Adjusted EPS: Expected to be in the range of $0.93 to $1.01.
Capital Expenditures: Expected to be in the range of $175 million to $225 million for 2026.
Net Leverage Ratio: Anticipated to improve further in 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Where is the company in its strategy to realign the business around higher-growth end markets, and was there any benefit from a volume or mix shift in Q1?
A:The company is focused on cross-business unit activity and strategic selling in key segments. In Q1, Sterigenics achieved 1.6% volume and mix growth, despite weather impacts. The quarter started slow but finished strong, and the outlook for the second quarter is optimistic.
Q:What is the current capacity utilization across different modalities, and does the company have sufficient capacity for future growth?
A:The company targets 80% capacity utilization and is in a good spot overall. A new X-ray modality facility will come online later this year, with another scheduled for late 2027 or early 2028. Customer satisfaction scores have improved significantly year-over-year.
Q:Does the company still see Q1 as the lightest quarter for Sterigenics, and what are the trends in core med devices and bioprocessing volumes?
A:Q1 is expected to be the lightest quarter, with similar growth anticipated in Q2. Med devices had a solid quarter, and bioprocessing volumes were significantly up year-over-year, though it remains a small portion of the total business.
Q:What were the volume trends for Sterigenics as the quarter progressed, and what are the expectations going forward?
A:January and February were softer due to weather, but March had the best volume in 3-4 years. April started strong, and the company is optimistic about continued growth, supported by a new X-ray facility and a customer conversion expected later in the year.
Q:What are the expectations for margins throughout the year, and what are the key drivers?
A:The company expects margin improvement driven by operating leverage in Sterigenics, with stable margins in other segments. This follows strong margin improvement in the previous year.
Q:Why is there a potential slowdown in Sterigenics' growth in Q2 compared to Q1, excluding weather impacts?
A:The slowdown is primarily due to a strong Q2 in the previous year, making it a tough comparison.
Q:What is the outlook for Nelson Labs in terms of testing growth, expert advisory services, and margins?
A:Nelson Labs' testing volumes were slightly down, but routine volumes are recovering. Margins are expected to stabilize in the low to mid-30s, consistent with previous guidance.
Q:What is the durability of Sterigenics' margins in the context of inflation, and is there an opportunity for incremental pricing?
A:Sterigenics is not significantly impacted by inflation and has set pricing to maintain a positive value gap. In Q1, pricing was slightly above the 4% guidance, and the business is well-positioned.
Q:Can you provide details on the large customer onboarding later this year and its impact on the guide?
A:The customer onboarding is included in the guidance and will occur late in the year. It is a meaningful but not massive addition, reinforcing the company's value proposition.
Q:What are the implications of potential changes to ethylene oxide emissions regulations, and how might this affect CapEx and opportunities?
A:The company is executing a $200 million CapEx plan for facility enhancements to meet current regulations, expected to be completed by 2026. The new proposed rule may create opportunities depending on its final form and timing. The company is well-positioned to meet any requirements.
Q:Why did Nordion pricing come in slightly below expectations, and is there any concern?
A:Nordion pricing was slightly below the usual range due to timing and customer mix, but there is no concern as price execution remains strong.
Q:What are the pricing assumptions for 2026, and have there been any changes by segment?
A:Pricing assumptions remain at 3-4%, with Nordion and Nelson Labs on the low end and Sterigenics on the high end. There are no changes to the outlook.
Q:Was there any extra selling day benefit in Q1, and how did it impact growth rates?
A:There was minimal impact from extra selling days in Q1.
Q:How is XPU (cross-product utilization) performing, and are there opportunities to accelerate penetration?
A:XPU had growth in Q1, supported by strong customer satisfaction scores and embedded labs within Sterigenics and Nelson Labs. The company continues to execute well in this area.
Q:Were there any significant maintenance downtimes in Q1, and what is the maintenance schedule for the rest of the year?
A:There were no significant maintenance downtimes in Q1. Downtime days are a headwind in the first half of the year but will become a tailwind in the second half.
Q:What is the expected growth for Nelson Labs in Q2?
A:Nelson Labs is expected to return to slight growth in Q2, around 1% or slightly below.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer regarding the potential impact of the Trump administration's proposed changes to ethylene oxide emissions regulations on top-line growth and CapEx. They stated uncertainty about the final rule and timing, focusing instead on compliance and safety measures.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Capital expenditure
Cobalt
Georgia
Investors section
Nordion currency
Petras
Phase causation
Sotera Health
Today
basis pricing
basis share
bellwether case
benefit currency
benefit pricing
case Phase
causation proceeding
chain
court
currency benefit
currency tailwind
development
equity
governance
health
income currency
injury case
interest
line expectation
low
mission
model
order
plaintiff causation
point currency
pricing currency
reminder
result line
science
SHC Transcript
Sotera Health Company (SHC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-8
Sotera Health Company (SHC) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Neutral6-3
Sotera Health Company (SHC) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Neutral5-19
Sotera Health Company (SHC) Q1 2026 Earnings Call Transcript
Unknown5-5
The earnings call summary presents a mixed picture. Financial performance is stable with slight growth, but there is a cautious tone in guidance and potential regulatory impacts. The Q&A reveals some concerns about growth slowdowns and regulatory changes, but also highlights operational resilience and customer satisfaction. The market cap suggests moderate sensitivity to these factors, leading to a neutral prediction for stock movement.
SHC Slides
Sotera Health Q1 2026 slides: earnings beat amid segment divergence2026-05-05
Sotera Health Q4 2025 slides: 20th year of growth, margins hit 51%2026-02-24
Sotera Health Q3 2025 slides: Revenue jumps 9.1%, company raises full-year guidance2025-11-04
Sotera Health Q2 2025 slides: revenue growth accelerates, EBITDA margins expand2025-08-08
SHC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
